Journal Options Oncology
Course Directors: Robert S. Mocharnuk, MD
Featured Expert Commentary
Susan M. O'Brien, MD
Professor of Medicine
Department of Leukemia
University of Texas M.D. Anderson Cancer Center
Houston, Texas
Recent Articles
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
Attal M, Harousseau JL, Leyvraz S, et al.
Blood. 2006;108:3289-3294.
Capsule Summary Expert Commentary Abstract Slides
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Chanan-Khan A, Miller KC, Musial L, et al.
J Clin Oncol. 2006;24:5343-5349.
Capsule Summary Expert Commentary Abstract Slides
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI, Kouroukis CT, White D, et al.
J Clin Oncol. 2007;25:1570-1575.
Capsule Summary Expert Commentary Abstract Slides
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Forstpointner R, Unterhalt M, Dreyling M, et al.
Blood. 2006;108:4003-4008.
Capsule Summary Expert Commentary Abstract Slides
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
Harousseau JL, Attal M, Leleu X, et al.
Haematologica. 2006;91:1498-1505.
Capsule Summary Expert Commentary Abstract Slides
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 Trial.
Moorman AV, Harrison CJ, Buck GA, et al.
Blood. 2007;109:3189-3197.
Capsule Summary Expert Commentary Abstract Slides
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S, Moore JO, Boyd TE, et al.
J Clin Oncol. 2007;25:1114-1120.
Capsule Summary Expert Commentary Abstract Slides
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
Walker R, Barlogie B, Haessler J, et al.
J Clin Oncol. 2007;25:1121-1128.
Capsule Summary Expert Commentary Abstract Slides
Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
Xicoy B, Ribera JM, Miralles P, et al.
Haematologica. 2007;92:191-198.
Capsule Summary Expert Commentary Abstract Slides
Therapeutic results in patients with relapsed diffuse large B cell non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation.
Ferrara F, Viola A, Copia C, et al.
Hematol Oncol. 2006;24:73-77.
Capsule Summary Expert Commentary Abstract Slides
|
Jointly sponsored by Medical Education Collaborative and Clinical Care Options, LLC.
Contact Info
Volume 2, Issue 1 Collection
Journal Options Oncology: Hematologic Malignancies, Volume 2, Issue 1
Course Director: Robert S. Mocharnuk, MD
  
- Bruce D. Cheson, MD
- Bruce Dezube, MD
- Frederick B. Hagemeister, MD
|
  
- Sagar Lonial, MD
- Craig H. Moskowitz, MD
- Liron Pantanowitz, MD
|
  
- Noopur Raje, MD
- Deborah A. Thomas, MD
- Steven P. Treon, MD, MA, PhD
|
Volume 1, Issue 1 Collection
|